抗肥満の世界市場レポート 2025

抗肥満市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は10.0％で、60億8,000万米ドルに成長します。予測期間の成長は、市場の拡大、世界化に起因しています。予測期間の主な動向には、研究開発、患者中心のアプローチ、保険適用、技術の進歩、デジタルヘルスと遠隔医療、新規薬物療法、肥満手術の進歩、otc（市販）ソリューション、行動介入、栄養・体重管理アプリなどがあります。

肥満は重大な世界的公衆衛生問題であり、その有病率は年々増加しています。例えば、2022年5月に発表された、英国を拠点とする肥満に特化した組織であるWorld Obesity Atlasの報告書では、2030年までに世界中で10億人以上が肥満の影響を受けると予測されています。この憂慮すべき動向は、加工食品や不健康食品の消費の増加、身体活動レベルの低下、肥満に伴うリスクに関する認識不足に起因すると考えられます。その結果、この世界の健康懸念に対処し、個人の体重管理努力を支援する緊急の必要性により、抗肥満薬の需要は今後増加する見通しです。このような需要の高まりは、抗肥満薬市場の拡大に寄与すると予想されます。

老年人口の増加は、今後の抗肥満薬市場の成長を牽引すると予想されます。老年人口には、通常65歳以上の高齢者が含まれ、この年齢層では肥満が依然として蔓延しており、重大な懸念事項となっています。高齢者、特に糖尿病患者は、身体活動の低下と血行障害により、特に肥満になりやすいです。例えば、2022年10月、米国を拠点とする保健専門機関である世界保健機関（WHO）の報告によると、世界全体では2030年までに6人に1人が60歳以上になるといいます。さらに、2050年までにこの年齢層の人口は倍増し、約21億人に達すると予測されています。その結果、高齢者人口の増加は抗肥満薬市場の重要な促進要因となっています。抗肥満薬は、肥満とそれに関連する健康問題の管理において高齢者特有のニーズに対応するものだからです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗肥満PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗肥満市場：成長率分析
• 世界の抗肥満市場の実績：規模と成長, 2019-2024
• 世界の抗肥満市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗肥満総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗肥満市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 末梢作用型抗肥満薬
• 中枢作用型抗肥満薬
• 世界の抗肥満市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方薬（Rx）
• 市販薬
• 世界の抗肥満市場薬による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 多剤療法
• 世界の抗肥満市場末梢作用型抗肥満薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オルリスタット
• ロルカセリン
• 世界の抗肥満市場中枢作用型抗肥満薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェンテルミン
• トピラマート
• ナルトレキソンとブプロピオンの併用
• リラグルチド

第7章 地域別・国別分析

• 世界の抗肥満市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗肥満市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗肥満市場：競合情勢
• 抗肥満市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Eisai Co. Ltd.
• Novo Nordisk A/S
• Zafgen Inc.
• Rhythm Pharmaceuticals Inc.
• Zydus Cadila
• Norgine B.V.
• Vivus Inc.
• Arena Pharmaceuticals Inc.
• Orexigen Therapeutics Inc.
• Eli Lilly and Company
• Amgen Inc.
• AstraZeneca PLC
• Novartis International AG
• Viking Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗肥満市場2029：新たな機会を提供する国
• 抗肥満市場2029：新たな機会を提供するセグメント
• 抗肥満市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-obesity drugs are pharmaceutical substances used to regulate or reduce a patient's weight. These drugs impact fundamental bodily functions related to weight control, targeting either appetite or calorie absorption. While diet and exercise remain the primary therapies for managing weight in overweight and obese individuals, anti-obesity drugs offer a supplementary option.

The key categories of anti-obesity drugs consist of peripherally acting anti-obesity medications and centrally acting anti-obesity medications. Peripherally acting anti-obesity drugs facilitate weight loss without affecting the brain or appetite. They work by inhibiting pancreatic lipase and impeding fat breakdown in the gastrointestinal tract, consequently reducing fat absorption in the intestine. These drugs are available in various forms, including prescription drugs (Rx) and over-the-counter (OTC) medications, offering both monotherapies and combination therapies to address weight management.

The anti-obesity market research report is one of a series of new reports from The Business Research Company that provides anti-obesity market statistics, including anti-obesity industry global market size, regional shares, competitors with an anti-obesity market share, detailed anti-obesity market segments, market trends and opportunities, and any further data you may need to thrive in the anti-obesity industry. This anti-obesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiobesity market size has grown rapidly in recent years. It will grow from $3.74 billion in 2024 to $4.15 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.

Obesity is a significant global public health issue, with its prevalence increasing each year. For example, a May 2022 report from the World Obesity Atlas, a UK-based organization focused on obesity, projected that by 2030, more than 1 billion individuals worldwide are expected to be affected by obesity. This alarming trend can be attributed to the growing consumption of processed and unhealthy foods, decreased physical activity levels, and a lack of awareness regarding the risks associated with obesity. Consequently, the demand for anti-obesity drugs is poised to rise in the future, driven by the urgent need to address this global health concern and support individuals in their weight management efforts. This growing demand is expected to contribute to the expansion of the anti-obesity drug market.

The increasing geriatric population is expected to drive the growth of the anti-obesity drugs market in the future. The geriatric population encompasses older individuals, typically aged 65 and above, and obesity remains a prevalent and significant concern within this age group. Elderly individuals, especially those with diabetes, are particularly susceptible to obesity due to reduced physical activity and impaired circulation. For example, in October 2022, reports from the World Health Organization, a specialized US-based health agency, indicated that globally, one in six individuals will be 60 years or older by 2030. Furthermore, by 2050, the number of individuals in this age group is projected to double, reaching approximately 2.1 billion. Consequently, the growing geriatric population is a significant driver of the anti-obesity drugs market, as it addresses the specific needs of older individuals in managing obesity and related health issues.

Major companies in the anti-obesity drugs market are dedicated to innovation, with a focus on developing new products to better serve their customers. One such innovative product is Mounjaro (tirzepatide), an anti-obesity drug designed to address the needs of adults with obesity or overweight conditions, particularly those with weight-related comorbidities. For example, in October 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched Mounjaro (tirzepatide), which received fast track designation approval from the Food and Drug Administration (FDA), a US-based federal agency. Mounjaro (tirzepatide) is an injectable anti-obesity drug that aims to assist individuals struggling with obesity in achieving their weight loss goals. It is indicated for use in adults with type 2 diabetes and, when combined with a diet and exercise regimen, can help improve blood sugar (glucose) control. This type of innovation demonstrates the commitment of these companies to providing effective solutions for individuals grappling with obesity and related health issues.

The pharmaceutical industry is currently experiencing a growing trend of mergers and acquisitions among companies specializing in drug development for metabolic disorders, which encompass conditions like obesity and diabetes. This strategic approach is adopted by pharmaceutical companies to bolster their drug portfolios in the field of metabolic diseases and to introduce safe and efficacious medications to the market. For example, companies like Evotec AG and Novo Nordisk have established a strategic alliance to collaborate on the discovery and development of drug molecules designed to treat metabolic disorders. These disorders include obesity, diabetes, and related health conditions. Such collaborations and partnerships represent an effort to pool resources, expertise, and innovation in the quest to bring novel and effective drugs to individuals dealing with metabolic disorders, thereby addressing a significant health challenge.

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiobesity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiobesity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Peripherally Acting Anti-Obesity Drugs; Centrally Acting Anti-Obesity Drugs
• 2) By Type: Prescription Drugs (Rx); OTC Drugs
• 3) By Medication: Monotherapies; Polytherapies
• Subsegments:
• 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat; Lorcaserin
• 2) By Centrally Acting Anti-Obesity Drugs: Phentermine; Topiramate; Naltrexone-Bupropion Combination; Liraglutide
• Companies Mentioned: F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antiobesity Market Characteristics

3. Antiobesity Market Trends And Strategies

4. Antiobesity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antiobesity Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antiobesity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antiobesity Market Growth Rate Analysis
• 5.4. Global Antiobesity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antiobesity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antiobesity Total Addressable Market (TAM)

6. Antiobesity Market Segmentation

• 6.1. Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripherally Acting Anti-Obesity Drugs
• Centrally Acting Anti-Obesity Drugs
• 6.2. Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Drugs (Rx)
• OTC Drugs
• 6.3. Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapies
• Polytherapies
• 6.4. Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Orlistat
• Lorcaserin
• 6.5. Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phentermine
• Topiramate
• Naltrexone-Bupropion Combination
• Liraglutide

7. Antiobesity Market Regional And Country Analysis

• 7.1. Global Antiobesity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antiobesity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiobesity Market

• 8.1. Asia-Pacific Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiobesity Market

• 9.1. China Antiobesity Market Overview
• 9.2. China Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiobesity Market

• 10.1. India Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiobesity Market

• 11.1. Japan Antiobesity Market Overview
• 11.2. Japan Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiobesity Market

• 12.1. Australia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiobesity Market

• 13.1. Indonesia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiobesity Market

• 14.1. South Korea Antiobesity Market Overview
• 14.2. South Korea Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiobesity Market

• 15.1. Western Europe Antiobesity Market Overview
• 15.2. Western Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiobesity Market

• 16.1. UK Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiobesity Market

• 17.1. Germany Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiobesity Market

• 18.1. France Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiobesity Market

• 19.1. Italy Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiobesity Market

• 20.1. Spain Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiobesity Market

• 21.1. Eastern Europe Antiobesity Market Overview
• 21.2. Eastern Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiobesity Market

• 22.1. Russia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiobesity Market

• 23.1. North America Antiobesity Market Overview
• 23.2. North America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiobesity Market

• 24.1. USA Antiobesity Market Overview
• 24.2. USA Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiobesity Market

• 25.1. Canada Antiobesity Market Overview
• 25.2. Canada Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiobesity Market

• 26.1. South America Antiobesity Market Overview
• 26.2. South America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiobesity Market

• 27.1. Brazil Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiobesity Market

• 28.1. Middle East Antiobesity Market Overview
• 28.2. Middle East Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiobesity Market

• 29.1. Africa Antiobesity Market Overview
• 29.2. Africa Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiobesity Market Competitive Landscape And Company Profiles

• 30.1. Antiobesity Market Competitive Landscape
• 30.2. Antiobesity Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antiobesity Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eisai Co. Ltd.
• 31.3. Novo Nordisk A/S
• 31.4. Zafgen Inc.
• 31.5. Rhythm Pharmaceuticals Inc.
• 31.6. Zydus Cadila
• 31.7. Norgine B.V.
• 31.8. Vivus Inc.
• 31.9. Arena Pharmaceuticals Inc.
• 31.10. Orexigen Therapeutics Inc.
• 31.11. Eli Lilly and Company
• 31.12. Amgen Inc.
• 31.13. AstraZeneca PLC
• 31.14. Novartis International AG
• 31.15. Viking Therapeutics Inc.

32. Global Antiobesity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiobesity Market

34. Recent Developments In The Antiobesity Market

35. Antiobesity Market High Potential Countries, Segments and Strategies

• 35.1 Antiobesity Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antiobesity Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antiobesity Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer